The Oligonucleotide Delivery System Market is predicted to grow at an 12.4% CAGR during the forecast period for 2024-2031.
The delivery system of an oligonucleotide refers to the method and technologies applied for transferring oligonucleotides into cells where they could exert their therapeutic effects. Oligonucleotides, due to their size and chemical properties, face the challenge of penetration through the biological barriers to enter target cells. Efficacy and safety are therefore directly connected to effective delivery, making it critical for the effectiveness of oligonucleotide therapies. It has different types of therapeutic agents, which are named as follows: Antisense Oligonucleotides (ASOs), Small Interfering RNAs (siRNAs), Aptamers, MicroRNAs (miRNAs).
One of the most significant drivers is increased investment in gene therapy. Gene therapies are gaining popularity, and funding along with research into effective delivery mechanisms of oligonucleotides is increasing. Yet another driver for the market is an increase in regulatory approvals. Regulatory approval not only validates the efficacy of the gene therapy but also incites investment in the gene therapy.
Competitive Landscape
Some of the Key Players in Oligonucleotide Delivery System Market:
- Biogen
- Sarepta Therapeutics, Inc.
- Jazz Pharmaceuticals plc
- Ionis Pharmaceuticals, Inc.
- Nippon Shinyaku Co., Ltd.
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Novartis AG
- Dicerna Pharmaceuticals, Inc. (Novo Nordisk)
- IVERIC bio, Inc. (Astellas Pharma Inc.)
- Elsie Biotechnologies (GSK)
Market Segmentation:
The oligonucleotide delivery system market is segmented by delivery system, disease indication. By delivery system market is segmented into conjugation-based delivery systems, nanoparticle-based delivery systems, exosome-based delivery systems, exosome-based delivery systems, liposomes, others. By conjugation-based delivery systems the market is sub segmented into GALNAc conjugation, ligand conjugation, antibody conjugation, targeting moiety conjugation. By nanoparticle-based delivery systems the market is sub segmented into lipid nanoparticles (LNPs), peptide nanoparticles. By viral vector-based delivery systems the market is sub segmented into adeno-associated virus (AAV) vectors, AAV9, lentiviral vectors, and others. By disease indication market is segmented into genetic disorders, infectious diseases, oncology, neurological disorders, others (autoimmune diseases, metabolic disorders, etc.)
Nanoparticle-based Delivery Systems is Expected to Drive the Oligonucleotide Delivery System Market
The growth of the oligonucleotide delivery market is attributed to nanoparticle-based delivery systems, including lipid nanoparticles and polymeric nanoparticles, due to their inherent ability to stabilize better cellular uptake and offering flexibility in the design. This makes it possible for oligonucleotides not to get degraded by nucleases until it reaches a target cell through the bloodstream. Also, LNPs are part of approved siRNA therapies called ONPATTRO and GIVLAARI. Nanoparticles can facilitate uptake by the cells via endocytosis and can be engineered with targeting ligands to increase their accuracy in delivery, thus minimizing off-target effects and enhancing efficacy in therapy. Their adaptive design allows changes in size, charge, and surface properties as well, which makes them better suited for a variety of therapeutic applications-from cancer, genetic disorders, to viral infections.
The Oncology Segment is Growing at the Highest Rate in the Oligonucleotide Delivery System Market.
Factors such as growing incidences of cancer, promising clinical outcomes, and rapid development in delivery technologies are the main drivers of such growth for the oncology segment. The leading cause of death worldwide, diagnosed cancer cases pose heavy demand for such innovative treatments as ASOs and siRNAs that can target genes which may be core to the progression of cancer. While no oligonucleotide drugs for cancer have been approved so far, several clinical trials in progress have given encouraging results and 229 trials were registered until early 2021.
Regionally, North America Led the Oligonucleotide Delivery System Market.
North America is expected to dominate the oligonucleotide delivery system market primarily due to its robust R&D infrastructure, high investment in life sciences, support by regulators, and a higher incidence of genetic disorders. This region, particularly the U.S., is considered to have a robust R&D environment supporting leading biotechnology companies and organizations that research innovative oligonucleotide treatments. Investment in life sciences drives the development of personalized therapeutics, such as oligonucleotide therapies. The U.S. FDA has been supportive of these therapies, and it has streamlined the approval process and encouraged further research.
Oligonucleotide Delivery System Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD XX.XX Bn |
|
Revenue Forecast In 2031 |
USD XX.XX Bn |
|
Growth Rate CAGR |
CAGR of 12.4% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Delivery System, Disease Indication and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
Biogen, Sarepta Therapeutics, Inc., Jazz Pharmaceuticals plc, Ionis Pharmaceuticals, Inc., Nippon Shinyaku Co., Ltd., AstraZeneca, Alnylam Pharmaceuticals, Inc., Novartis AG, Dicerna Pharmaceuticals, Inc. (Novo Nordisk), IVERIC bio, Inc. (Astellas Pharma Inc.), Elsie Biotechnologies (GSK) |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
